期刊
EUROSURVEILLANCE
卷 26, 期 21, 页码 -出版社
EUR CENTRE DIS PREVENTION & CONTROL
DOI: 10.2807/1560-7917.ES.2021.26.21.2100438
关键词
-
资金
- Horizon 2020 program of the European Commission (I-MOVECOVID-19) [101003673]
- Carlos III Institute of Health
- European Regional Development Fund [COV20/00542]
The study found that the COVID-19 vaccine had effectiveness rates of 35-66% against infections, 42-82% against symptomatic infection, and 72-95% against COVID-19 hospitalization. The effectiveness significantly increased with the second dose, supporting the recommendation for complete vaccination.
COVID-19 vaccine effectiveness was evaluated in close contacts of cases diagnosed during January-April 2021. Among 20,961 contacts, 7,240 SARS-CoV-2 infections were confirmed, with 5,467 being symptomatic and 559 leading to hospitalisations. Non-brand-specific one and two dose vaccine effectiveness were respectively, 35% (95% confidence interval (CI): 25 to 44) and 66% (95% CI: 57 to 74) against infections, 42% (95% CI: 31 to 52) and 82% (95% CI: 74 to 88) against symptomatic infection, and 72% (95% CI: 47 to 85) and 95% (95% CI: 62 to 99) against COVID-19 hospitalisation. The second dose significantly increased effectiveness. Findings support continuing complete vaccination.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据